Page 9 - Daniel Vitt News Today : Breaking News, Live Updates & Top Stories | Vimarsana

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023

EQS-News: Immunic, Inc : Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

Paula schwartzEdna kaplanFranziska burianekDaniel vittJessica breuRx communications groupExchange commissionDistribution servicesImmunic incPresents data from phaseClinical trialCeliac diseaseUnited european gastroenterology weekChief executive officerHuman trialBarrier regeneration

Vidofludimus calcium reduced NfL levels in progressive MS patients| Multiple Sclerosis News Today

Vidofludimus calcium reduced NfL levels in progressive MS patients| Multiple Sclerosis News Today
multiplesclerosisnewstoday.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from multiplesclerosisnewstoday.com Daily Mail and Mail on Sunday newspapers.

Andreas muehlerJens kuhleDaniel vittUniversity hospital baselImmunic therapeutics

Immunic Presents Data from Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023, the 9th Joint ECTRIMS-ACTRIMS Meeting

NEW YORK - Immunic, Inc. , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, announced that.

United statesRobertj foxDaniel vittJessica breuMellen centerNeurological instituteImmunic incExchange commissionStaff neurologistMultiple sclerosisCoordinating investigatorChief executive officerNeurofilament light chainVidofludimus calciumPoster numberPrivate securities litigation reform act

Immunic (IMUX) Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis

Immunic (IMUX) Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesDaniel vittRobertj foxMellen centerNeurological instituteImmunic incStaff neurologistMultiple sclerosisCleveland clinicCoordinating investigatorChief executive officerNeurofilament light chainVidofludimus calciumPoster number

Immunic super excited about latest PMS trial data

Immunic Inc (NASDAQ:IMUX) President and CEO Dr Daniel Vitt speaks to Thomas Warner from Proactive after the biotechnology company announced encouraging.

Thomas warnerDaniel vittImmunic inc